{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:32:55Z","timestamp":1786120375856,"version":"build-2736575974"},"reference-count":53,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,1]]},"DOI":"10.1097\/sga.0b013e31823ff0e8","type":"journal-article","created":{"date-parts":[[2012,2,3]],"date-time":"2012-02-03T04:24:13Z","timestamp":1328243053000},"page":"12-21","source":"Crossref","is-referenced-by-count":8,"title":["Practical Considerations for Recognizing and Managing Severe Irritable Bowel Syndrome"],"prefix":"10.1097","volume":"35","author":[{"given":"Lucinda A.","family":"Harris","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret M.","family":"Heitkemper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"issue":"Suppl 1","key":"R1-2-20210207","first-page":"S1","article-title":"An evidence-based position statement on the management of irritable bowel syndrome.","volume":"104","year":"2009","journal-title":"American Journal of Gastroenterology"},{"issue":"6","key":"R2-2-20210207","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1053\/gast.2002.37095b","article-title":"American Gastroenterological Association medical position statement: irritable bowel syndrome.","volume":"123","year":"2002","journal-title":"Gastroenterology"},{"issue":"10","key":"R3-2-20210207","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1111\/j.1365-2036.2005.02671.x","article-title":"Prevalence and demographics of irritable bowel syndrome: Results from a large Web-based survey.","volume":"22","author":"Andrews","year":"2005","journal-title":"Alimentary Pharmacology and Therapeutics"},{"issue":"7","key":"R4-2-20210207","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1093\/ajhp\/62.7.700","article-title":"Rationale for using serotonergic agents to treat irritable bowel syndrome.","volume":"62","author":"Baker","year":"2005","journal-title":"American Journal of Health-System Pharmacy"},{"issue":"6","key":"R5-2-20210207","first-page":"521","article-title":"The patients perspective of irritable bowel syndrome.","volume":"50","author":"Bertram","year":"2001","journal-title":"Journal of Family Practice"},{"issue":"5","key":"R6-2-20210207","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1002\/hup.1038","article-title":"Duloxetine in the treatment of irritable bowel syndrome: an open-label pilot study.","volume":"24","author":"Brennan","year":"2009","journal-title":"Human Psychopharmacology"},{"issue":"4","key":"R7-2-20210207","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1038\/ajg.2009.25","article-title":"The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review.","volume":"104","author":"Brenner","year":"2009","journal-title":"American Journal of Gastroenterology"},{"issue":"14","key":"R8-2-20210207","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1001\/archinte.161.14.1733","article-title":"A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome.","volume":"161","author":"Camilleri","year":"2001","journal-title":"Archives of Internal Medicine"},{"issue":"9209","key":"R9-2-20210207","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/S0140-6736(00)02033-X","article-title":"Efficacy and safety of alosetron in women with irritable bowel syndrome: A randomised, placebo-controlled trial.","volume":"355","author":"Camilleri","year":"2000","journal-title":"Lancet"},{"issue":"11","key":"R10-2-20210207","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1111\/j.1572-0241.2004.30509.x","article-title":"Long-term safety and efficacy of alosetron in women with severe diarrhea-predominant irritable bowel syndrome.","volume":"99","author":"Chey","year":"2004","journal-title":"American Journal of Gastroenterology"},{"issue":"5","key":"R12-2-20210207","doi-asserted-by":"crossref","first-page":"242","DOI":"10.4088\/PCC.v07n0507","article-title":"Treatment of irritable bowel syndrome: Changing the paradigm.","volume":"7","author":"Coon","year":"2005","journal-title":"Primary Care Companion to the Journal of Clinical Psychiatry"},{"issue":"Suppl 8","key":"R13-2-20210207","first-page":"S252","article-title":"The role of serotonin in the pathophysiology of irritable bowel syndrome.","volume":"7","author":"Crowell","year":"2001","journal-title":"American Journal of Managed Care"},{"issue":"8","key":"R14-2-20210207","doi-asserted-by":"crossref","first-page":"626","DOI":"10.7326\/0003-4819-145-8-200610170-00012","article-title":"Treatment for bacterial overgrowth in the irritable bowel syndrome.","volume":"145","author":"Drossman","year":"2006","journal-title":"Annals of Internal Medicine"},{"issue":"12","key":"R15-2-20210207","doi-asserted-by":"crossref","first-page":"2897","DOI":"10.1038\/ajg.2009.341","article-title":"Beyond tricyclics: New ideas for treating patients with painful and refractory functional gastrointestinal symptoms.","volume":"104","author":"Drossman","year":"2009","journal-title":"American Journal of Gastroenterology"},{"issue":"6","key":"R17-2-20210207","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1097\/MCG.0b013e318189a7f9","article-title":"International survey of patients with IBS: Symptom features and their severity, health status treatments, and risk taking to achieve clinical benefit.","volume":"43","author":"Drossman","year":"2009","journal-title":"Journal of Clinical Gastroenterology"},{"issue":"3","key":"R19-2-20210207","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1136\/gut.2008.163162","article-title":"Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: Systematic review and meta-analysis.","volume":"58","author":"Ford","year":"2009","journal-title":"Gut"},{"issue":"Suppl 2","key":"R20-2-20210207","first-page":"S25","article-title":"Serotonin and its implication for the management of irritable bowel syndrome.","volume":"3","author":"Gershon","year":"2003","journal-title":"Review of Gastroenterology Disorders"},{"issue":"3","key":"R21-2-20210207","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1053\/gast.2000.16484","article-title":"The impact of irritable bowel syndrome on health-related quality of life.","volume":"119","author":"Gralnek","year":"2000","journal-title":"Gastroenterology"},{"issue":"3","key":"R22-2-20210207","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1046\/j.1365-2036.1997.00160.x","article-title":"Patient-perceived severity of irritable bowel syndrome in relation to symptoms, health resource utilization and quality of life.","volume":"11","author":"Hahn","year":"1997","journal-title":"Alimentary Pharmacology and Therapeutics"},{"issue":"65","key":"R23-2-20210207","first-page":"1","article-title":"Treatments for irritable bowel syndrome: Patients attitudes and acceptability.","volume":"8","author":"Harris","year":"2008","journal-title":"BMC Complementary and Alternative Medicine"},{"issue":"7603","key":"R24-2-20210207","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1136\/bmj.39199.679236.AE","article-title":"Psychological approach to managing irritable bowel syndrome.","volume":"334","author":"Hayee","year":"2007","journal-title":"British Medical Journal"},{"issue":"7","key":"R25-2-20210207","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/S1542-3565(04)00242-3","article-title":"Self-management for women with irritable bowel syndrome.","volume":"2","author":"Heitkemper","year":"2004","journal-title":"Clinical Gastroenterology Hepatology"},{"issue":"6","key":"R26-2-20210207","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1097\/00001610-200111000-00005","article-title":"Irritable bowel syndrome. A survey of nurses knowledge.","volume":"24","author":"Heitkemper","year":"2001","journal-title":"Gastroenterology Nursing"},{"issue":"11","key":"R27-2-20210207","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1111\/j.1365-2036.2005.02463.x","article-title":"Irritable bowel syndrome in the United States: Prevalence, symptom patterns and impact.","volume":"21","author":"Hungin","year":"2005","journal-title":"Alimentary Pharmacology and Therapeutics"},{"issue":"1","key":"R28-2-20210207","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/00042737-200501000-00003","article-title":"Cognitive behaviour therapy for irritable bowel syndrome.","volume":"17","author":"Hutton","year":"2005","journal-title":"European Journal of Gastroenterology Hepatology"},{"issue":"12","key":"R30-2-20210207","doi-asserted-by":"crossref","first-page":"3004","DOI":"10.1038\/ajg.2009.479","article-title":"Comprehensive self-management for irritable bowel syndrome: Randomized trial of in-person vs. combined in-person and telephone sessions.","volume":"104","author":"Jarrett","year":"2009","journal-title":"American Journal of Gastroenterology"},{"issue":"7651","key":"R31-2-20210207","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1136\/bmj.39524.439618.25","article-title":"Components of placebo effect: Randomised controlled trial in patients with irritable bowel syndrome.","volume":"336","author":"Kaptchuk","year":"2008","journal-title":"British Medical Journal"},{"issue":"8","key":"R32-2-20210207","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1111\/j.1572-0241.2007.01282.x","article-title":"A randomized, double-blind, placebo-controlled study to assess efficacy and safety of 0.5 mg and 1 mg alosetron in women with severe diarrhea-predominant IBS.","volume":"102","author":"Krause","year":"2007","journal-title":"American Journal of Gastroenterology"},{"issue":"8","key":"R33-2-20210207","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.cgh.2008.03.004","article-title":"Self-administered cognitive behavior therapy for moderate to severe irritable bowel syndrome: Clinical efficacy, tolerability, feasibility.","volume":"6","author":"Lackner","year":"2008","journal-title":"Clinical Gastroenterology Hepatology"},{"issue":"1","key":"R34-2-20210207","first-page":"1","article-title":"Irritable bowel syndrome and disease severity: Are we undertreating our patients Expert Reviews in Gastroenterology H","volume":"4","author":"Lacy","year":"2010","journal-title":"epatology"},{"issue":"4","key":"R35-2-20210207","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1177\/1756283X09104794","article-title":"Review: The treatment of irritable bowel syndrome.","volume":"2","author":"Lacy","year":"2009","journal-title":"Therapeutic Advances in Gastroenterology"},{"issue":"8","key":"R36-2-20210207","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S1542-3565(05)00157-6","article-title":"Irritable bowel syndrome: Toward an understanding of severity.","volume":"3","author":"Lembo","year":"2005","journal-title":"Clinical Gastroenterology and Hepatology"},{"issue":"8","key":"R37-2-20210207","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S1542-3565(04)00284-8","article-title":"Effect of alosetron on bowel urgency and global symptoms in women with severe, diarrhea-predominant irritable bowel syndrome: Analysis of two controlled trials.","volume":"2","author":"Lembo","year":"2004","journal-title":"Clinical Gastroenterology Hepatology"},{"issue":"9","key":"R38-2-20210207","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.1111\/j.1572-0241.2001.04128.x","article-title":"Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome.","volume":"96","author":"Lembo","year":"2001","journal-title":"American Journal of Gastroenterology"},{"issue":"1","key":"R39-2-20210207","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1586\/egh.09.72","article-title":"Alosetron for severe diarrhea-predominant irritable bowel syndrome: Safety and efficacy in perspective.","volume":"4","author":"Lewis","year":"2010","journal-title":"Expert Reviews in Gastroenterology Hepatology"},{"issue":"7","key":"R40-2-20210207","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1001\/jama.292.7.852","article-title":"Small intestinal bacterial overgrowth: A framework for understanding irritable bowel syndrome.","volume":"292","author":"Lin","year":"2004","journal-title":"JAMA"},{"issue":"12","key":"R41-2-20210207","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/S1542-3565(04)00545-2","article-title":"Suicidal ideation in patients with irritable bowel syndrome.","volume":"2","author":"Miller","year":"2004","journal-title":"Clinical Gastroenterology and Hepatology"},{"issue":"3","key":"R44-2-20210207","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1053\/j.gastro.2004.11.050","article-title":"Lactobacillus and bifidobacterium in irritable bowel syndrome: Symptom responses and relationship to cytokine profiles.","volume":"128","author":"OMahony","year":"2005","journal-title":"Gastroenterology"},{"issue":"2","key":"R45-2-20210207","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/00004836-198106000-00009","article-title":"Treatment of the irritable bowel syndrome with Bentyl (dicyclomine hydrochloride).","volume":"3","author":"Page","year":"1981","journal-title":"Journal of Clinical Gastroenterology"},{"issue":"6","key":"R46-2-20210207","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1053\/gast.2002.37286","article-title":"The growing case for hypnosis as adjunctive therapy for functional gastrointestinal disorders.","volume":"123","author":"Palsson","year":"2002","journal-title":"Gastroenterology"},{"issue":"2","key":"R47-2-20210207","first-page":"412","article-title":"Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. A double-blind, randomized, placebo-controlled study.","volume":"98","author":"Pimentel","year":"2003","journal-title":"American Journal of Gastroenterology"},{"issue":"1","key":"R48-2-20210207","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1004409","article-title":"Rifaximin therapy for patients with irritable bowel syndrome without constipation.","volume":"364","author":"Pimentel","year":"2011","journal-title":"New England Journal of Medicine"},{"issue":"12","key":"R52-2-20210207","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.cca.2009.01.028","article-title":"Role of serotonin in gastrointestinal motility and irritable bowel syndrome.","volume":"403","author":"Sikander","year":"2009","journal-title":"Clinica Chimica Acta"},{"issue":"Suppl 1","key":"R53-2-20210207","first-page":"S119","article-title":"Patient-reported symptom relief from current therapy is a robust marker of illness severity in IBS abstract 865.","volume":"5","author":"Spiegel","year":"2010","journal-title":"Gastroenterology"},{"issue":"16","key":"R54-2-20210207","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1001\/archinte.164.16.1773","article-title":"Clinical determinants of health-related quality of life in patients with irritable bowel syndrome.","volume":"164","author":"Spiegel","year":"2004","journal-title":"Archives of Internal Medicine"},{"issue":"11","key":"R56-2-20210207","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1017\/S1092852900019854","article-title":"Cognitive-behavioral treatment of irritable bowel syndrome.","volume":"10","author":"Toner","year":"2005","journal-title":"CNS Spectrums"},{"issue":"4","key":"R57-2-20210207","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/ajg.2010.12","article-title":"Evolution of clinical trials for irritable bowel syndrome: Issues in end points and study design.","volume":"105","author":"Trentacosti","year":"2010","journal-title":"American Journal of Gastroenterology"},{"issue":"2","key":"R61-2-20210207","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.1572-0241.2001.03525.x","article-title":"Alosetron improves quality of life in women with diarrhea-predominant irritable bowel syndrome.","volume":"96","author":"Watson","year":"2001","journal-title":"American Journal of Gastroenterology"},{"issue":"1112","key":"R62-2-20210207","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1111\/j.1365-2036.2004.02256.x","article-title":"The usual medical care for irritable bowel syndrome.","volume":"20","author":"Whitehead","year":"2004","journal-title":"Alimentary Pharmacology and Therapeutics"},{"issue":"4","key":"R63-2-20210207","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1053\/gast.2002.32392","article-title":"Systematic review of the comorbidity of irritable bowel syndrome with other disorders: What are the causes and implications G","volume":"122","author":"Whitehead","year":"2002","journal-title":"astroenterology"},{"issue":"7","key":"R64-2-20210207","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1111\/j.1572-0241.2006.00734.x","article-title":"Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome.","volume":"101","author":"Whorwell","year":"2006","journal-title":"American Journal of Gastroenterology"},{"issue":"11","key":"R65-2-20210207","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1111\/j.1365-2036.2006.02928.x","article-title":"Determinants of healthcare-seeking behavior among subjects with irritable bowel syndrome.","volume":"23","author":"Williams","year":"2006","journal-title":"Alimentary Pharmacology and Therapeutics"},{"issue":"5","key":"R66-2-20210207","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1111\/j.1365-2036.2006.03028.x","article-title":"Systematic review: The effectiveness of hypnotherapy in the management of irritable bowel syndrome.","volume":"24","author":"Wilson","year":"2006","journal-title":"Alimentary Pharmacology and Therapeutics"}],"container-title":["Gastroenterology Nursing"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/SGA.0b013e31823ff0e8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T20:34:20Z","timestamp":1786048460000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00001610-201201000-00002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1]]},"references-count":53,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/sga.0b013e31823ff0e8","relation":{},"ISSN":["1042-895X"],"issn-type":[{"value":"1042-895X","type":"print"}],"subject":[],"published":{"date-parts":[[2012,1]]}}}